Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection.

1. PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic
presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy
skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently,
drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s
PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV
infection.
Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy,
such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of
next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm.
GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable
side-effect profiles and decreased duration of therapy compared with the current standard of care.
Scope
Overview of hepatitis C virus, including epidemiology, etiology, general symptoms from infection, and
national vaccination recommendations and guidelines. Annualized hepatitis C therapeutics market revenue,
annual cost of vaccination and treatment usage pattern data from 2012 and forecast for nine years to 2022. Key
topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial
mapping and implications for the hepatitis C market. Pipeline analysis: comprehensive data split across
different phases, and emerging trends, specifically interferon-free therapies and fixed-dose combinations.
Analysis of the current and future market competition in the global hepatitis C therapeutics market. Insightful
review of the key industry and governmental drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs and
high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,
patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10
year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our
models support data presented in the reports and the complete methodology is outlined in the report and the
model.
*Model only available with site and global license purchases.
Key Findings
Patient awareness is anticipated to increase in response to government education and screening initiatives.
Interferon use is predicted to decrease over the next 10 years. The launch of next-generation, direct-acting
antivirals is expected to streamline the HCV treatment algorithm. The approval of more-tolerable HCV
therapies is likely to result in patients deciding to undergo treatment (i.e., decrease in the warehouse effect).
Key Questions Answered in this Report
What is the fate of Vertex’s Incivek and Merck’s Victrelis after the launch of next-generation
HCV therapies? What role, if any, will interferon have in the HCV treatment algorithm over the next decade?
Is there demand from physicians for new interferon derivatives? What metrics do physicians use when
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

2. evaluating HCV regimens? Is pill burden a major unmet need in this indication? Which HCV regimen in
development are physicians most excited about? As direct-acting antivirals (DAAs) overtake the HCV
treatment algorithm, is there any need for host-targeting therapies?
Key Benefits
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and
technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by
understanding the trends shaping and driving the global hepatitis C therapeutics market. Drive revenues by
understanding the key trends, innovative products and technologies, market segments, and companies likely to
impact the global hepatitis C market in future. Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analyzing the performance of various competitors. Identify
emerging players with potentially strong product portfolios and create effective counter-strategies to gain a
competitive advantage. Track drug sales in the global hepatitis C therapeutics market from 2012–2022.
Organize your sales and marketing efforts by identifying the market categories and segments that present
maximum opportunities for consolidations, investments and strategic partnerships.
table Of Contents
1table Of Contents2
1.1list Of Tables9
1.2list Of Figures12
2hcv: Executive Summary14
2.1hcv Market Is Expected To Grow During The Forecast Period14
2.2pharma Giants Battle As New Entrants Leverage Next-generation Hcv Regimens To Capture Market
Share16
2.3companies Prioritize Improving The Side Effect Profile And Duration Of Therapy Of Hcv Regimens17
2.4new Entrants Welcomed In The Market After The Launch Of Next-generation Hcv Regimens17
2.5launch Of Interferon-free Regimens Will Fundamentally Change The Hcv Treatment Algorithm In The
Us, Japan, And Many European Countries18
2.6what Do The Physicians Think?19
3introduction20
3.1catalyst20
3.2related Reports20
3.3upcoming Related Reports20
4disease Overview21
4.1etiology And Pathophysiology21
4.1.1etiology21
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

3. 4.1.2pathophysiology24
4.1.3prognosis25
4.2symptoms25
5epidemiology27
5.1risk Factors And Comorbidities27
5.1.1the Risk Of Contracting Hcv Is Almost 50 Times Higher Among Injection Drug Users28
5.1.2there Is A 10.9-fold Increased Risk Of Developing Hcv Infection Through A Blood Transfusion28
5.1.3no Current Preventative Therapy To Reduce Perinatal Transmission29
5.1.4metabolic Syndrome Is A Common Comorbidity In Hcv-infected Individuals29
5.1.5chronic Alcoholism Greatly Magnifies The Risk Of Hcc30
5.1.6hepatitis B Virus And Hcv Share Similar Modes Of Transmission, Resulting In Co-infections30
5.1.7hcv/hiv Co-infection Complicates Treatment Options And Accelerates Liver Damage30
5.2global Trends31
5.2.1us31
5.2.25eu32
5.2.3japan34
5.2.4brazil35
5.2.5china35
5.3forecast Methodology36
5.3.1sources Used36
5.3.2forecast Assumptions And Methods39
5.3.3forecast Assumptions And Methods (hcv Genotypes)42
5.3.4sources Not Used45
5.4epidemiology Forecast (2012–2022)45
5.4.1total Prevalent Cases Of Hcv45
5.4.2age-specific Prevalent Cases Of Hcv47
5.4.3sex-specific Prevalent Cases Of Hcv50
5.4.4age-standardized Prevalence Of Hcv52
5.4.5hcv Genotype Class Distributions53
5.5discussion54
5.5.1conclusion On Epidemiology Trends54
5.5.2limitations Of The Analysis55
5.5.3strengths Of The Analysis55
6disease Management57
6.1diagnosis And Referral Overview57
6.2treatment Overview57
6.3us60
6.3.1diagnosis60
6.3.2clinical Practice61
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

4. 6.4france63
6.4.1diagnosis63
6.4.2clinical Practice64
6.5germany65
6.5.1diagnosis65
6.5.2clinical Practice65
6.6italy66
6.6.1diagnosis66
6.6.2clinical Practice66
6.7spain67
6.7.1diagnosis67
6.7.2clinical Practice67
6.8uk67
6.8.1diagnosis67
6.8.2clinical Practice68
6.9japan69
6.9.1diagnosis69
6.9.2clinical Practice69
6.10brazil70
6.10.1diagnosis70
6.10.2clinical Practice70
6.11china70
6.11.1diagnosis70
6.11.2clinical Practice71
7competitive Assessment72
7.1overview72
7.2strategic Competitor Assessment72
7.3product Profiles – Major Brands73
7.3.1incivek (telaprevir)73
7.3.2victrelis (boceprevir)79
7.3.3pegasys (peginterferon Alfa-2a)83
7.3.4pegintron (peginterferon Alfa-2b)88
7.3.5copegus, Rebetol, And Generic Ribavirin92
7.3.6therapeutic Class: Interferon96
8opportunity And Unmet Need97
8.1overview97
8.2unmet Needs97
8.2.1unmet Need: Treatment Tolerability97
8.2.2unmet Need: Efficacy98
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

5. 8.2.3unmet Need: Disease Awareness98
8.2.4unmet Need: Treatment Cost99
8.2.5unmet Need: Shorter Treatment Duration100
8.2.6unmet Need: Simplified Treatment Regimens100
8.3unmet Needs Gap Analysis100
8.4opportunities101
8.4.1opportunity: Pan-genotypic Hcv Regimen101
8.4.2opportunity: Treatment Of Underrepresented Patient Populations101
8.4.3opportunity: Involvement Of Immune System102
9pipeline Assessment103
9.1overview103
9.2clinical Trial Mapping103
9.2.1clinical Trials By Country103
9.3clinical Trials By Phase And Trial Status104
9.4promising Drugs In Clinical Development105
9.4.1sofosbuvir And Sofosbuvir/ledipasvir107
9.4.2simeprevir116
9.4.3abt-450 Plus Abt-267 And Abt-333123
9.4.4faldaprevir And Faldaprevir Plus Bi 207127129
9.4.5daclatasvir And Daclatasvir Plus Asunaprevir136
9.4.6vaniprevir145
9.4.7other Drug Classes149
10current And Future Players153
10.1overview153
10.2trends In Corporate Strategy155
10.3company Profiles155
10.3.1merck155
10.3.2roche157
10.3.3vertex158
10.3.4janssen160
10.3.5gilead161
10.3.6abbvie163
10.3.7bristol-myers Squibb164
10.3.8boehringer Ingelheim166
10.4additional Companies With Promising Drugs167
10.4.1mitsubishi Tanabe167
10.4.2glaxosmithkline168
10.4.3achillion169
10.4.4scynexis169
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

6. 10.4.5idenix170
10.4.6presidio170
11market Outlook172
11.1global Markets172
11.1.1forecast172
11.1.2drivers And Barriers – Global Issues175
11.2us179
11.2.1forecast179
11.2.2key Events184
11.2.3drivers And Barriers185
11.3france188
11.3.1forecast188
11.3.2key Events193
11.3.3drivers And Barriers194
11.4germany195
11.4.1forecast195
11.4.2key Events200
11.4.3drivers And Barriers200
11.5italy202
11.5.1forecast202
11.5.2key Events205
11.5.3drivers And Barriers206
11.6spain207
11.6.1forecast207
11.6.2key Events211
11.6.3drivers And Barriers212
11.7uk213
11.7.1forecast213
11.7.2key Events217
11.7.3drivers And Barriers218
11.8japan220
11.8.1forecast220
11.8.2key Events224
11.8.3drivers And Barriers225
11.9brazil226
11.9.1forecast226
11.9.2key Events230
11.9.3drivers And Barriers230
11.10china231
11.10.1forecast231
11.10.2key Events234
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

7. 11.10.3drivers And Barriers235
12appendix237
12.1bibliography237
12.2abbreviations255
12.3methodology256
12.4forecasting Methodology256
12.4.1percent Drug-treated Patients257
12.4.2patient Warehousing257
12.4.3drugs Included In Each Therapeutic Class257
12.4.4launch And Patent Expiry Dates257
12.4.5general Pricing Assumptions258
12.4.6individual Drug Assumptions259
12.4.7generic Erosion261
12.4.8selection Of Pipeline Agents261
12.4.9pricing Of Pipeline Agents261
12.5physicians And Specialists Included In This Study265
12.6survey Of Prescribing Physicians267
12.7about The Authors268
12.7.1author268
12.7.2epidemiologist268
12.7.3global Head Of Healthcare268
12.8about Globaldata269
12.9contact Us269
12.10disclaimer269
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

8. Website: http://www.researchmoz.us/
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022